Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. - Wikidata - wikimedia - TriplyDB

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

http://www.wikidata.org/entity/Q34113933

about

Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Deciphering the distance to antibiotic resistance for the pneumococcus using genome sequencing data Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice Risk factors associated with colonization by pneumococci with reduced susceptibility to fluoroquinolones in adult outpatients.High genetic diversity of ciprofloxacin-nonsusceptible isolates of Streptococcus pneumoniae in Poland.Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method.Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.A population-based analysis of pneumococcal disease mortality in California, 1989-1998.Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Pharmacodynamics of antimicrobials: treatment optimisation.Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC.Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates.Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Emerging drugs for pneumococcal pneumonia.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.Factors influencing fluoroquinolone resistance.Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.Quinolone resistance among pneumococci: therapeutic and diagnostic implications.Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.

P2860

Q30251593-96D0FCA1-E6B4-4316-94CA-962AE4D9C840 Q31162440-E7BB268B-FF20-4FD9-B148-EF1EFD2155D9 Q33264145-77C6408A-664D-43A5-B976-E6BB12BF7465 Q33675920-D0EA00BA-3E93-49C0-BA78-54AC65C5EB27 Q33752905-4C462C46-57C1-4E65-9B9F-5BF9E7EAB443 Q33770218-7D988F13-056A-4EA3-886F-1CF474F1E5FC Q33807463-FE62F806-F550-4CA8-A4BA-B42F49C25001 Q34352053-3EE2E216-01C0-47C2-B89D-D175224B25AD Q34428419-D84F127F-DAF0-43B1-BC7F-FF82D22A903D Q34478323-5F333B20-53BC-45B5-81BB-618DE484EA0A Q34502866-62794AA6-7A78-47B4-AB20-BDD88F5DA522 Q34510372-27B8A27C-32DB-4419-875B-BB52FB828634 Q34757031-3A507FD1-42FA-4B46-9DB6-D372F07A5A95 Q35026714-6F6FA47A-A6C5-490F-BB16-57E2690CBE95 Q35125137-6715D83E-5283-4FDB-BB26-4DD3FF130E65 Q35685125-58261445-3AD2-48CB-8106-B1CE2DBF4010 Q35917226-03E9856F-453A-4543-AB39-478A8E4DCF39 Q36009308-AE5F6118-02C8-4E95-80D1-64BBFCCDCEEC Q36048301-21C8F234-87C8-4107-B082-B30E63AE9CCA Q36337074-A92CC086-52E9-4710-85C6-1671AEEBF449 Q36544935-8521D054-77A3-429B-9C98-95B6CBA5A460 Q36670897-04FFCEB1-B6BB-44B8-9D2F-816F01557A53 Q36728602-4DE602DF-82BB-44C5-BE95-56FBFA6F2EF0 Q36880109-C623FC4C-F461-4F54-A90A-379246AE2EAF Q37120372-99FC2A15-E18E-43C4-A9C9-B3BCCBD80514 Q37489226-AF1563EF-F4F4-4CDE-8A75-F8784C1AD6B0 Q37511259-3CE32B49-F7DB-40F0-B48E-A5F123D56D36 Q37568953-A493ED23-191B-484D-A21E-384855425D38 Q37733449-53B9D3A8-5C4C-4729-9BD4-CE88BE771F34 Q37864327-B89AA404-E437-4667-92AB-5D93EB427123 Q37868241-389D1E61-08F8-48BB-9984-C3986036274F Q37998398-9D543010-40A9-46D7-ACED-E94A370F92DB Q38523119-88EC01CE-92D7-45E0-9DFC-592CE8EE7379 Q40130516-27FF9724-E3A9-43DC-BF84-E1E8EF15094F Q41976061-23ECA931-CE8F-42F1-BBFA-CAC1BE8FEDDD Q42041266-AEA0AF59-324D-4498-80FE-2641E9D43F2C Q42590584-134870D4-611A-4982-ACDE-225D2C2CA8C3 Q42686155-F392594B-380B-4374-B080-3E9867CCA753 Q44883946-29B6D85A-10BF-4685-B7C2-F35A0D0A07C0 Q46704604-10903B4B-5254-44D8-8299-427BF260C566

P2860

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

http://www.wikidata.org/entity/Q34113933

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@ast

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@en

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@nl

type

label

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@ast

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@en

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@nl

prefLabel

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@ast

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@en

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@nl

P1433

Q34113933-28C7FF84-8546-4821-8ACA-3F2381479DC3

P1476

Q34113933-6DDF03DA-50F6-4C5A-8EE0-2CD038C7C0A1

P2093

Q34113933-175B532F-90FD-451B-A349-63AAD5315D16

Q34113933-355CEE6E-FE16-45C8-AB67-2B1EBF308C65

Q34113933-7E53FB83-D18C-4E84-A697-D6D65EC1AD86

Q34113933-8D20B3B2-6C62-4314-9668-81F13C2A4AD1

Q34113933-B97EFC60-B733-4A54-9695-B42BB1FF7282

Q34113933-DA01FD36-9135-4931-940B-6CD80EB64AAB

Q34113933-F96BD8A5-3CE2-4C10-A5BF-A4B6A193F17C

P2860

Q34113933-00D83669-8803-4D47-BDD6-D057812A4FCC

Q34113933-10995CA7-04F8-40A5-A11A-B5898B233757

Q34113933-1F72299B-DFAB-4916-AA87-B6526F8A3002

Q34113933-26BBD4C5-FF0B-48E4-9F50-5370785C95C4

Q34113933-47FD8053-7BE6-4E15-8C6C-0AF3B7E0432E

Q34113933-48AAFD32-3147-41AC-BAFD-519AF352DE21

Q34113933-4C44EF44-478F-4010-A36B-3153E02FB14A

Q34113933-535DB007-E18D-48F0-AE76-BDF10E9D0741

Q34113933-575AFE2E-2083-4B6E-933E-9B11392F78DF

Q34113933-58E28D5E-7E58-41F0-9E20-4DF3BBFC99D5

P304

Q34113933-703F812F-0CA5-4FD1-9ACB-AC6152962C04

P31

Q34113933-E0A357F5-F207-4382-A408-941268A28D48

P356

Q34113933-14DBC3B7-A2B7-44E4-BABF-57055607D6B4

P407

Q34113933-314AB9FE-EB46-43A4-9C29-EF5704C0F0A2

P433

Q34113933-556B1216-B19C-4673-B1A3-AFBC953BD1AC

P478

Q34113933-BDA7229B-0CB7-4B57-8C80-4E02CEFE5CAB

P50

Q34113933-046CD2E0-022B-415A-A083-457EFFEB8F80

P577

Q34113933-58682184-0FED-4734-842B-EDCC54297EDB

P698

Q34113933-FDFD0B73-A4AB-4D84-B903-C9454D54A740

P921

Q34113933-813A8515-1CCE-4F6A-8B6E-158E06E53B1D

P932

Q34113933-8E6A106E-4B6D-4F1F-ADEC-CC9F2CCBB0C1

P356

AAC.46.3.680-688.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

@en

P2093

Angela B Brueggemann

http://www.w3.org/2001/XMLSchema#string

Angela Nilius

http://www.w3.org/2001/XMLSchema#string

Gary V Doern

http://www.w3.org/2001/XMLSchema#string

Holly Huynh

http://www.w3.org/2001/XMLSchema#string

Laurel Almer

http://www.w3.org/2001/XMLSchema#string

Paul Rhomberg

http://www.w3.org/2001/XMLSchema#string

Stacy L Coffman

http://www.w3.org/2001/XMLSchema#string

P2860

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

P304

680-688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.3.680-688.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11850248

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

127509

http://www.w3.org/2001/XMLSchema#string